Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zunyi Medical Univ. hMAO-B compound 16
- Development stage
- Unknown
- Lead developer
- Zunyi Medical University
01
Overview
Zunyi Medical Univ. hMAO-B compound 16: sourced facts only. name: "The most potent compound identified in the study, compound 16, exhibited significant hMAO-B inhibition (IC50 = 0.011 μM) and remarkable selectivity (selectivity index > 3636) over hMAO-A." [PMID:41224694]; target: "The most potent compound identified in the study, compound 16, exhibited significant hMAO-B inhibition (IC50 = 0.011 μM) and remarkable selectivity (selectivity index > 3636) over hMAO-A." [PMID:41224694]; developer: "School of Bioengineering, Zunyi Medical University, Zhuhai, China." [PMID:41224694]
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on Zunyi Medical Univ. hMAO-B compound 16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zunyi Medical Univ. hMAO-B compound 16.